human TNF driven polyarthritis (Tg197)
A humanized transgenic mouse overexpressing human TNF resulting in the spontaneous development of chronic arthritis closely resembling the pathology of human rheumatoid arthritis. It is an ideal model for the efficacy evaluation of anti-hTNF therapeutics.
human tmTNF driven arthritis (Tg5453)
A humanized transgenic mouse with deregulated expression of transmembrane human TNF resulting in the spontaneous development of arthritis pathology. This model is a unique tool for the assessment of the efficacy of anti-hTNF agents in the blockade of the transmembrane form of human TNF.
human TNF driven slow progressing arthritis (Tg3647)
A humanized TNF transgenic mouse overexpressing human TNF resulting in the spontaneous development of late onset, slow progression, long lasting arthritis more closely resembling adult onset of human rheumatoid arthritis.
human TNF-TNFR1 driven arthritis (Tg197hTNFR1KI)
A humanized transgenic mouse overexpressing human TNF in the context of human TNFR1 that results in the spontaneous development of arthritis pathology closely resembling that of the human rheumatoid arthritis. This mouse offers a completely humanized model for the TNF-TNFR1 signaling pathway, ideal for the evaluation both of anti-hTNF & anti-hTNFR1 therapeutics.
mouse TNF driven spondyloarthritis (TNFΔARE)
A mouse mutant with deregulated mouse TNF expression resulting in the gradual development of spontaneous inflammatory poly-arthritis and inflammatory bowel disease. An ideal model for the evaluation of small molecule inhibitors in two disease models simultaneously.
Collagen Antibody Induced Arthritis (CAIA)
A highly reproducible & consistent preclinical efficacy evaluation mouse model of rheumatoid arthritis that can be used for the fast evaluation of candidate therapeutic agents targeting pathogenic mechanisms and inflammatory processes of arthritis.
human TNF driven CAIA
CAIA induction in Tg1278TNFko mice results in a fast, sensitive and higly reproducible arthritis mouse model ideal for the efficacy evaluation of anti-human TNF therapeutics.